Our Mission
We created this company because we know the frustrations that come with antibodies that don't work. Our goal is to provide you with only antibodies and other reagents and services that you know are real and will work.
Our Platform
At GenuIN Biotechnologies, our ShGE™ gene silencing platform enables us to perform high-throughput and low-cost antibody validation. We have optimized and streamlined our platform- Nobody else has, or can say they match, this biotechnology we designed.
By using lentivirus-mediated short hairpin RNA (shRNA), we knock down gene expression, significantly reducing or eliminating target proteins. This approach allows us to rigorously test antibody specificity. (Antibody specificity is defined as the ability of an antibody to bind to and only to its target antigen)
We combine this technology with advanced techniques like Western blotting, immunocytochemistry, and flow cytometry to deliver unmatched accuracy.
Why shRNA knockdown?
Genetic verification is considered a gold standard for antibody validation, according to the International Working Group of Antibody Validation (IGWAV). Among genetic approaches, gene knockout (KO) at the genomic level and gene knockdown (KD) at the mRNA level using small interference RNA (siRNA) and short hairpin RNA (shRNA) techniques have been widely used for antibody validation.
We choose shRNA because compared to KO and siRNA approaches, shRNA KD offers the following benefits, 1) lentiviral shRNA can be stably integrated into a cell’s genome and result in a more complete knockdown compared to siRNA; 2) It is particularly powerful for difficult-to-target and nondividing cells; 3) It knocks down rather than knocks out a gene, so it is particularly useful for the study of genes vital to cell survival.
Using KO for a gene leads to the complete ablation of its encoded protein, making it lethal for genes essential to cell survival. Using siRNA to knock down genes is cost-effective and less time-consuming, but the knockdown is transient in and of itself.
At GenuIN, our goal is to continue to increase the number of KD-validated antibodies we can offer. Along the way, our gene silencing platform gives us lentivirus, cell line, and cell lysate libraries that we can use to provide additional, high quality products and services.